Kishnani, P., Bratkovic, D., Byrne, B., Díaz-Manera, J., Laforêt, P., Mozaffar, T., … Schoser, B. (2022). eP157: Efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study. In Genetics in Medicine (Vol. 24, pp. S96–S96). Elsevier BV. https://doi.org/10.1016/j.gim.2022.01.193

Kishnani, Priya, Drago Bratkovic, Barry Byrne, Jordi Díaz-Manera, Pascal Laforêt, Tahseen Mozaffar, Ans van der Ploeg, et al. “eP157: Efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study.” In Genetics in Medicine, 24:S96–S96. Elsevier BV, 2022. https://doi.org/10.1016/j.gim.2022.01.193.

Kishnani P, Bratkovic D, Byrne B, Díaz-Manera J, Laforêt P, Mozaffar T, et al. eP157: Efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study. In: Genetics in Medicine. Elsevier BV; 2022. p. S96–S96.

Kishnani, Priya, et al. “eP157: Efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study.” Genetics in Medicine, vol. 24, no. 3, Elsevier BV, 2022, pp. S96–S96. Crossref, doi:10.1016/j.gim.2022.01.193.

Kishnani P, Bratkovic D, Byrne B, Díaz-Manera J, Laforêt P, Mozaffar T, van der Ploeg A, Roberts M, Toscano A, Jiang H, Sitaraman S, Goldman M, Castelli J, Schoser B. eP157: Efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study. Genetics in Medicine. Elsevier BV; 2022. p. S96–S96.